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Pachyonychia congenita (PC) comprises a group of rare autosomal dominant genetic disorders that
involve ectodermal dysplasia. It is characterized by hypertrophic nail dystrophy, focal palmoplantar
keratoderma, follicular keratoses, and oral leukokeratosis. Historically, PC has been subdivided into two
subtypes, PC-1 or PC-2, on the basis of clinical presentation. However, differential diagnosis based on
clinical grounds, especially in young and/or not fully penetrant patients, can be difﬁcult. In addition,
clinical analysis of the large case series has shown that there is considerable phenotypic overlap between
these two subtypes recently. Based on the advent of molecular genetics and the identiﬁcation of the
genes causing PC, more speciﬁc nomenclature has been adopted. Therefore, diagnosis at the molecular
level is useful and important to conﬁrm the clinical impression. In this report, we describe two typical
cases of PC with mutation analysis revealed a small deletion (514_516delACC, Asn172del) and a point
mutation (487 G > A, GAG/ AAG, Glu163Lys) in the KRT6A gene.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Pachyonychia congenita (PC), a rare autosomal-dominant ecto-
dermal dysplasia caused bymutations in one of a number of keratin
genes, is characterized by hypertrophic nail dystrophy, focal pal-
moplantar keratoderma and blistering, oral leukokeratosis, cyst
formation, palmoplantar hyperhidrosis, and follicular keratoses on
the trunk and extremities.
Historically, PC has been subdivided into two subtypes, PC-1 or
PC-2, on the basis of clinical presentation.1 However, the causative
mutations were identiﬁed in several PC patients currently and
more speciﬁc molecular genetic nomenclature has been adopted by
causative genes,2,3 which include KRT6A, KRT6B, KRT16 and
KRT17.4,5
Genetic analysis of PC not only conﬁrms the clinical diagnosis
but also aids in genetic counseling. Only two cases of PC (one is
PC1 and another is PC2) have been previously reported in Taiwan
but without genetic analysis.6,7 In this report, we describe two
typical cases of PC with mutation analysis and review of the
literature.partment of Dermatology,
Hospital, No. 138, Sheng Li
416; fax: þ886 2766180.
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Case 1
A36-year-oldTaiwanesemanpresentedwithmarked thickeningof all
20nailspresent since infancyandpalmoplantarhyperkeratosiswhich
had developed during childhoodwith painful bullae makingwalking
and participation in sports difﬁcult. It was not clear whether natal or
neonatal teeth were present. The patient’s intelligence was normal.
The patient’s father had similar abnormally thickened nails but
declined clinical examination. He is unmarried and has no offspring.
Physical examination revealed marked thickening of all ﬁnger
and toe nails (Figures 1A and B), callus-like focal plantar kerato-
derma on the palms and soles (Figure 1C), hyperhidrosis, and leu-
kokeratosis of the tongue (Figure 1D). Potassium hydroxide mounts
and fungal cultures of the ﬁnger and toenails showed negative
results. In addition, there were numerous cysts and nodules of
various sizes all over the patient’s body (Figure 1E). Excision biopsy
of one cystic lesion from the chest showed steatocystoma. Therewas
no evidence of ocular, hair, or dental lesions. Based on the charac-
teristic clinical ﬁndings, a diagnosis of PC type 1 (PC1) was made.
Case 2
A 45-year-old Taiwanese man presented with marked thickening of
all 20 nails present since birth with rough and discolored surface,
and subungual hyperkeratosis was apparent (Figure 2). Nails evern. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Clinical manifestations of pachyonychia congenita type 1. (A) Marked thickening of all ﬁnger; (B) toe nails; (C) callus-like plantar keratoderma on the heels; (D) leuko-
keratosis of the tongue; (E) numerous cysts and nodules of various sizes all over the patient’s body.
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same characteristics as the previous nails. Focal palmoplantar
hyperkeratosis was mild without blistering and did not bring any
discomfort to the patient. Only occasional cysts or nodules over the
patient’s body were noted. It was not clear whether natal or
neonatal teeth were present. No obvious other characterized clin-
ical features of PC were noted. He is unmarried and has no
offspring. He denied that any member of his family, including his
parents and siblings, had the same presentation as himself. He also
mentioned that a number of methods have been tried to solve the
thickened nail problem but none had any obvious effect.Polymerase chain reaction ampliﬁcation and automated sequencing
Genomic DNA was extracted from peripheral blood from the
patient with the informed consent. The DNA sample was then
subjected to mutation screening by ampliﬁcation of segments of
KRT6A and KRT16 gene.
For polymerase chain reaction (PCR) ampliﬁcation, approxi-
mately 200 ng of genomic DNA, 12.8 pmol/L of each primer,
10 mmole/L dNTP and 1.25 U of AmpliTaq Gold (Perkin Elmer, Roche
Molecular Systems, Inc., Branchburg, NJ USA) were used in a total
volume of 50 mL. The oligonucleotide primers designed to amplify
the mutation in exon 1 of the KRT6A gene are: forward primer,
Figure 2 Clinical manifestations of Case 2. Marked thickening of all ﬁnger and toe nails was noted since birth. These nails show typical prominent hypertrophic nail dystrophy with
a rough and discolored surface.
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TCCCTGGCAGe3’. The product size is a 683 base pair. The ampliﬁ-
cation conditions were 94C for 5 minutes, followed by 35 cycles of
94C for 45 seconds, annealing temperature (60C) for 45 seconds
and 72C for 45 seconds, and extension at 72C for 10 minutes. The
PCR products were examined on 2% agarose gel. The PCR product
was subjected to direct automated sequencing (377 ABI Advanced
Biotechnologies, Columbia, MD USA).
Direct genome sequencing of case 1 revealed a small deletion
mutation (514_516delACC, Asn172del) (Figures 3A and B) in the
Exon 1 of KRT6A and Case 2 revealed a point mutation (487 G > A,
GAG/ AAG, Glu163Lys) of KRT6A, respectively (Figures 3C and D).
Discussion
PC is a rare autosomal dominant genodermatosis and has been
linked to mutations in four keratin genes that are expressed in the
epithelia, KRT6A, KRT6B, KRT16, and KRT17.4,5 Historically, PC was
ﬁrst described by Muller8 in the early twentieth century and has
been subdivided into two subtypes, PC-1 (JadassohneLewandowski
type) or PC-2 (JacksoneLawler type), under the classiﬁcation
proposed by Schonfeld1 on the basis of the clinical presentation.
Jadassohn-Lewandowsky type PC (PC1) is characterized by
onychogryphosis, focal palmoplantar keratoderma, follicular
hyperkeratosis, and leukoplakia of the oral mucosa.9 It is associated
with mutations in the keratin 16 gene, or its expression partner
keratin 6A.10,11 In addition to the features seen in type 1, Jackson-
Lawler type PC (PC2) is characterized by bullae, palmoplantar
hyperhidrosis, and cysts arising from the hair follicle infundibulum
and sebaceous duct (eruptive vellus hair cysts and steatocysto-
mas).12 Other ﬁndings in PC2 include natal teeth, hair abnormalities
(pili torti), and hidradenitis suppurativa.13 However, a considerable
phenotypic overlap between these two subtypes was found and
case reports with misdiagnosis or cases with coincidental ﬁndingsunrelated to PC is possible.2 It was not until the early 1990swith the
emergence of molecular genetics technology that the causative
gene was mapped to one of the keratin gene clusters.14 Shortly
thereafter, the causative mutations were identiﬁed in several PC
patients. Therefore, a combination of factors have led to the
suggestion that PC should be reclassiﬁed including identiﬁcation of
the causative genes of PC can provide a rational means of classifying
patients and the considerable phenotypic overlap between the two
PC-1 and PC-2 was found by large case series analysis.2 Recently,
more speciﬁc molecular genetic nomenclature has been adopted by
the International Pachyonychia Congenita Consortium. In this
system, PC-6a, PC-6b, PC-16, and PC-17 refer to cases withmutation
identiﬁed in the genes KRT6A, KRT6B, KRT16, and KRT17, respec-
tively. PC-U designates cases of suspected PC, where either
a mutation has not been found or not been investigated.2,3
To date, the majority of those reported mutations fall within the
highly conserved helix boundary motifs of each keratin gene.15
These regions are thought to be vital for end-to-end overlap
interactions during the elongation phase of ﬁlament assembly.16
A large mutational study in PC was performed and shows
approximately one-half of the kindreds had mutations in KRT6A
(52%), 28% hadmutations in KRT16, 17% in KRT17, and 3% of families
had mutations in KRT6B.2 This mutation analysis study also iden-
tiﬁes mutation hotspot codons of PC. The most common PC
mutation is the p.Asn172del mutation that, to date, has been found
in 32 out of 221 PC families (14%) with known mutations.
In Taiwan, there are only two previous case reports describing
PC but with no genetic analysis.6,7 Our case report of these two
patients is the ﬁrst report of PC in Taiwan with mutation analysis
(514_516delACC, Asn172del in the exon 1 of KRT6A) and (487 G> A,
GAG/ AAG, Glu163Lys of KRT6A), which is on the mutation hot-
spot of PC.
In PC, there can also be variation in clinical severity between
mutations in the same gene and even between individuals with the
Figure 3 (A) Automated DNA sequencing of KRT6A revealed a heterozygous 514_516delACC (Asn172del) mutation in Case 1; (B) normal sequence from control; (C) Case 2 shows
point mutation (487 G > A, GAG/ AAG, Glu163Lys) of KRT6A; (D) normal sequence from control.
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mental factors, lifestyle, and patient care may account for some of
this clinical variation.2 These factors may explain the variation in
severity and clinical appearance between our two patients who
have the same mutation gene (KRT6A). Therefore, an important
conclusion is that PC can really be considered as a spectrum of
phenotypes ranging from very mild to more severe.
In 2003, a patient advocacy groupdPachyonychia Congenita
Projectdwas established to support those affected by PC and to
both encourage and fund research into a cure for the condition. To
achieve this goal, the International PC Consortium was founded in
early 2004. This is a group of clinicians and scientists actively
researching the causes of PC and, more importantly, the develop-
ment of new treatments for PC.3
Various forms of treatment have been proposed for the skin and
nail problems associated with PC, including keratolytic agents and
lubricants, oral retinoids,1,7,17 high doses of vitamin A,18 vitamin E,
X-ray therapy, protective footwear, topical aluminum chloride,19
and Botulinum toxin.20 None of these measures have produced
any permanent solution to the distressing morbidity primarily
related to the painful hyperkeratosis and blistering of the soles.
Although it is a rare condition, PC is at the forefront of genetic
therapy development in the dermatologic ﬁeld. In particular, the
dominant-negative genetic mechanism in PC contributes to ther-
apeutic strategies based on RNA interference, especially in the form
of short interfering RNA (siRNA). Targeting the speciﬁc mutation
by siRNA to down-regulate the mutant protein is currently being
investigated.21 It has been demonstrated thatmutant keratin alleles
differing from wild type by a single-nucleotide point mutation can
be potently and speciﬁcally silenced by carefully designed siRNA.22
This mutation-speciﬁc siRNA therapy approach has been pro-
gressed into the recently reported small-scale human clinical trial,
in which efﬁcacy was demonstrated.23 This was the ﬁrst time that
siRNA had been used to treat a human skin disorder. The identiﬁ-
cation of mutations in case of PC is not only important for con-
ﬁrming the diagnosis but also for gene-speciﬁc treatments.Acknowledgments
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